Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)
NCT ID: NCT06234436
Last Updated: 2024-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
EARLY_PHASE1
10 participants
INTERVENTIONAL
2023-12-07
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Plasma exchange
1-20 plasma exchanges.
Plasma exchenge
Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma exchenge
Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
MoCA score \< 27 and \>17
Able to give informed consent as judged by the doctor setting the AD diagnosis and study doctor.
At least one biomarker of the AT(N)-classification system supporting the diagnosis
Expected to live more than five years at inclusion by the study doctor.
Exclusion Criteria
Known severe protein S depletion
Previous severe allergic reaction after transfusion of a blood product
Known heart failure
Known liver failure
Known kidney failure
Previous cancer \<10 years.
Not deemed able to participate by the study staff
Other severe chronic diseases, interfering with the TPE-procedure
Ongoing infections
Other unresolved medical conditions
Known coagulopathies
Fulfilling ICD-10 criteria for dementia at baseline, as evaluated by the evaluating physician.
Peripheral veins not expected to be suitable for repeated venous access procedures.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Impetus Grants (EIN: 87-1540960)
UNKNOWN
The National Association for Public Health, Norway
OTHER_GOV
Vestre Viken Hospital Trust
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arne Vasli Lund Søraas
PI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
520697
Identifier Type: -
Identifier Source: org_study_id